Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(3.02)
# 1,311
Out of 4,759 analysts
123
Total ratings
37.96%
Success rate
1.3%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $31.57 | +200.92% | 10 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $179.94 | +19.49% | 5 | Feb 20, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $220 → $260 | $145.74 | +78.40% | 2 | Feb 18, 2025 | |
| SEPN Septerna | Reiterates: Overweight | $50 | $6.43 | +677.60% | 2 | Feb 11, 2025 | |
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $0.78 | +541.85% | 4 | Dec 20, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $200 | $30.64 | +552.74% | 6 | Dec 11, 2024 | |
| TRML Tourmaline Bio | Reiterates: Overweight | $25 | $14.38 | +73.85% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Reiterates: Overweight | n/a | $1.26 | - | 5 | Dec 11, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Overweight | $65 | $8.77 | +641.16% | 4 | Nov 19, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Overweight | $30 | $10.85 | +176.50% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.07 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.44 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $33.28 | +170.43% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.37 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $74.89 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.97 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.55 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.76 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $70.74 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.74 | +1,916.13% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $30.29 | +74.98% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $5.36 | +329.10% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $36.50 | +78.08% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $43.46 | +38.06% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.85 | +2,602.70% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $26.72 | +180.69% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $1.49 | +235.57% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.53 | +618.95% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $113.04 | +15.00% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $707.51 | +7.42% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $12.00 | +25.00% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $8.71 | +531.46% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.67 | +1,696.41% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.69 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $6.34 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $331.41 | -24.56% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3,500 → $4,600 | $4.00 | +114,900.00% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.79 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $33.81 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.26 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $16.69 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $12.23 | +79.89% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.53 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $72.23 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $214.29 | -55.67% | 1 | Aug 17, 2017 |
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $31.57
Upside: +200.92%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $179.94
Upside: +19.49%
Ascendis Pharma
Feb 18, 2025
Maintains: Outperform
Price Target: $220 → $260
Current: $145.74
Upside: +78.40%
Septerna
Feb 11, 2025
Reiterates: Overweight
Price Target: $50
Current: $6.43
Upside: +677.60%
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $0.78
Upside: +541.85%
Janux Therapeutics
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $30.64
Upside: +552.74%
Tourmaline Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.38
Upside: +73.85%
Zura Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.26
Upside: -
Rocket Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $65
Current: $8.77
Upside: +641.16%
ARS Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $10.85
Upside: +176.50%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.07
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.44
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $33.28
Upside: +170.43%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.37
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $74.89
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.97
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.55
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.76
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.74
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.74
Upside: +1,916.13%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $30.29
Upside: +74.98%
Aug 13, 2024
Initiates: Overweight
Price Target: $23
Current: $5.36
Upside: +329.10%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $36.50
Upside: +78.08%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $43.46
Upside: +38.06%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.85
Upside: +2,602.70%
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $26.72
Upside: +180.69%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $1.49
Upside: +235.57%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.53
Upside: +618.95%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $113.04
Upside: +15.00%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $707.51
Upside: +7.42%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $12.00
Upside: +25.00%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $8.71
Upside: +531.46%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.67
Upside: +1,696.41%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.69
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $6.34
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $331.41
Upside: -24.56%
Jun 19, 2018
Upgrades: Outperform
Price Target: $3,500 → $4,600
Current: $4.00
Upside: +114,900.00%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $70.79
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $33.81
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.26
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $16.69
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $12.23
Upside: +79.89%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.53
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $72.23
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $214.29
Upside: -55.67%